SU11248 inhibits KIT and platelet-derived growth factor receptor beta in preclinical models of human small cell lung cancer.
about
The treatment landscape in thyroid cancer: a focus on cabozantinibPreclinical Murine Models for Lung Cancer: Clinical Trial ApplicationsIndividualising treatment choices in a crowded treatment algorithmPrimary and secondary kinase genotypes correlate with the biological and clinical activity of sunitinib in imatinib-resistant gastrointestinal stromal tumorThe outcome and predictive factors of sunitinib therapy in advanced gastrointestinal stromal tumors (GIST) after imatinib failure - one institution study.Heme oxygenase-1 is a predictive biomarker for therapeutic targeting of advanced clear cell renal cell carcinoma treated with sorafenib or sunitinib.Sunitinib in the treatment of metastatic renal cell carcinomaLysyl oxidase plays a critical role in endothelial cell stimulation to drive tumor angiogenesisThe 4q12 amplicon in malignant peripheral nerve sheath tumors: consequences on gene expression and implications for sunitinib treatment(3)D [corrected] quantification of tumor vasculature in lymphoma xenografts in NOD/SCID mice allows to detect differences among vascular-targeted therapiesMulticenter, phase II trial of sunitinib in previously treated, advanced non-small-cell lung cancer.Role of the ubiquitin proteasome system in renal cell carcinoma.Treatment outcomes of sunitinib treatment in advanced renal cell carcinoma patients: a single cancer center experience in KoreaPhase II study of sunitinib as second-line treatment for advanced gastric cancer.Sunitinib in combination with paclitaxel plus carboplatin in patients with advanced solid tumors: phase I study resultsPhase I and pharmacokinetic study of sunitinib in pediatric patients with refractory solid tumors: a children's oncology group study.A phase I dose-escalation and pharmacokinetic study of sunitinib in combination with pemetrexed in patients with advanced solid malignancies, with an expanded cohort in non-small cell lung cancerA phase I study of sunitinib combined with modified FOLFOX6 in patients with advanced solid tumors.Sunitinib in combination with gemcitabine for advanced solid tumours: a phase I dose-finding study.Phase I study of sunitinib plus S-1 and cisplatin in Japanese patients with advanced or metastatic gastric cancer.Sunitinib combined with pemetrexed and carboplatin in patients with advanced solid malignancies--results of a phase I dose-escalation study.Sunitinib treatment for patients with clear-cell metastatic renal cell carcinoma: clinical outcomes and plasma angiogenesis markersClinical outcomes of patients with advanced gastrointestinal stromal tumors: safety and efficacy in a worldwide treatment-use trial of sunitinib.Final results from the large sunitinib global expanded-access trial in metastatic renal cell carcinoma.Emerging data with antiangiogenic therapies in early and advanced non-small-cell lung cancer.Safety and efficacy of sunitinib in patients from Latin America: subanalysis of an expanded access trial in metastatic renal cell carcinoma.Maintenance Sunitinib following Initial Platinum-Based Combination Chemotherapy in Advanced-Stage IIIB/IV Non-Small Cell Lung Cancer: A Randomized, Double-Blind, Placebo-Controlled Phase III Study-CALGB 30607 (Alliance).Tolerability and pharmacokinetic profile of a sunitinib powder formulation in pediatric patients with refractory solid tumors: a Children's Oncology Group studyPharmacokinetically guided sunitinib dosing: a feasibility study in patients with advanced solid tumours.New chemical scaffolds for human african trypanosomiasis lead discovery from a screen of tyrosine kinase inhibitor drugsQuantification of sunitinib in mouse plasma, brain tumor and normal brain using liquid chromatography-electrospray ionization-tandem mass spectrometry and pharmacokinetic application.Complete longitudinal analyses of the randomized, placebo-controlled, phase III trial of sunitinib in patients with gastrointestinal stromal tumor following imatinib failure.A phase 1/pharmacokinetic study of sunitinib in combination with highly active antiretroviral therapy in human immunodeficiency virus-positive patients with cancer: AIDS Malignancy Consortium trial AMC 061.Understanding and managing toxicities of vascular endothelial growth factor (VEGF) inhibitorsPhase III randomized trial of sunitinib versus capecitabine in patients with previously treated HER2-negative advanced breast cancer.Pharmacologic modulation of niche accessibility via tyrosine kinase inhibition enhances marrow and thymic engraftment after hematopoietic stem cell transplantation.Inhibition of drug-resistant mutants of ABL, KIT, and EGF receptor kinasesInvestigational agents in development for the treatment of ovarian cancerAn exploratory study of sunitinib plus paclitaxel as first-line treatment for patients with advanced breast cancer.Sunitinib in combination with docetaxel in patients with advanced solid tumors: a phase I dose-escalation study
P2860
Q26796404-3269CE39-F579-42B8-831B-67CA0A8ECCA2Q26863474-D9B5E875-51E8-4DD5-9C1E-4C35DEC81C9FQ27023669-B45FB82D-4FA7-4560-A212-330E8D26AB73Q27851455-108F8E95-15B6-488D-89E3-9BDB26D63A3EQ27851744-EF0B5708-543F-4252-AF0E-7DFA4BCE3B4CQ27853203-F4BEB54A-FF2A-43F6-B460-344EBC62DBFCQ28072057-870B437F-ADA9-4560-B328-4C8D74F511E7Q28280138-5E3EC495-FEFC-4F70-8110-8596F07D3332Q28474942-FB57A8B2-FA89-442D-AB14-B0AFCCB61835Q28488869-66474B20-3462-46B2-8543-51819AD65173Q30422736-39782D34-DB3F-4547-8A96-157234A68057Q33307879-FEB470D0-E1F7-4FE2-9D2B-86B853639CB7Q33385981-BE2C2133-38DF-493F-A2BD-A48A48983C99Q33389519-422A4041-B460-4B2B-90FB-C034D57E33E2Q33393174-13C32C54-614F-4CFC-B902-20750BDD5DB2Q33395853-00A57758-722E-4FA8-9867-0216CA09984EQ33397590-DCDC1BDE-F3C3-4A0B-8777-567CCBA04EBDQ33401396-E7586331-1191-46DD-A296-FAB049081627Q33406542-6E73AA4C-B275-463C-B7FC-F8C7E7AA7D78Q33407676-90E20F0C-49D8-4431-BDB6-4F05B7081B32Q33409913-BF972EB0-F438-4FA4-823E-C7E94D9789E9Q33417933-D4C87D95-BC20-45C0-B733-D1F04FA88CC3Q33420123-9430DD40-9E20-4E6D-BC57-828A8BC2ACDBQ33423740-6232B4A4-8156-4677-8107-8C09C0E0040DQ33429478-69461D3A-9240-4824-A47D-7BE9A88E2D0AQ33435816-BDA9AA49-A07B-4BCD-889E-6931BD0640F0Q33439007-AA71D1D5-DEE1-4896-82CA-3F26D9B0D033Q33559444-B618E22C-E88D-46F1-B0EE-7285958C1A63Q33613666-748BDA4C-C939-476F-9AA1-2F1A092D3A78Q33622982-A3710D28-8EF8-4BA6-A329-EE4E2CCC6969Q33624207-D9100F3F-AAFA-4923-9751-C89A3B91A57FQ33648995-5669345A-08A9-4C15-B855-D078A3B563D3Q33686288-E3A2BB0B-7842-443C-90EA-039A69DFA148Q33698419-83C74DE6-CA39-4E6D-B79D-CAEA2521D079Q33794403-435AFA03-3275-444D-963B-8E43406964C8Q33871518-70CB559D-9FCA-4209-B8F5-97CD9606A5CAQ33906140-9F9FCF8D-5AEA-416E-82C6-D5715FA638BFQ33920800-EF6D8DA3-FAB6-4B91-ACA8-277D0D1B54EAQ33932531-275D1C04-0B6D-4C68-98FC-54D8EC9C4222Q33996608-2482F8CE-D3C2-4854-B313-E1F1BD0ECE59
P2860
SU11248 inhibits KIT and platelet-derived growth factor receptor beta in preclinical models of human small cell lung cancer.
description
2003 nî lūn-bûn
@nan
2003年の論文
@ja
2003年論文
@yue
2003年論文
@zh-hant
2003年論文
@zh-hk
2003年論文
@zh-mo
2003年論文
@zh-tw
2003年论文
@wuu
2003年论文
@zh
2003年论文
@zh-cn
name
SU11248 inhibits KIT and plate ...... human small cell lung cancer.
@en
type
label
SU11248 inhibits KIT and plate ...... human small cell lung cancer.
@en
prefLabel
SU11248 inhibits KIT and plate ...... human small cell lung cancer.
@en
P2093
P1476
SU11248 inhibits KIT and plate ...... human small cell lung cancer.
@en
P2093
Julie M Cherrington
Lesley J Murray
Leslie B Lee
Nancy K Pryer
Tinya J Abrams
P304
P577
2003-05-01T00:00:00Z